Recent developments in immunotherapy of cancers caused by human papillomaviruses
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Recent developments in immunotherapy of cancers caused by human papillomaviruses
Authors
Keywords
-
Journal
IMMUNOLOGY
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2020-11-18
DOI
10.1111/imm.13285
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Phase II evaluation of nivolumab in the treatment of persistent or recurrent cervical cancer (NCT02257528/NRG-GY002)
- (2020) Alessandro D. Santin et al. GYNECOLOGIC ONCOLOGY
- Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study
- (2019) Hyun Cheol Chung et al. JOURNAL OF CLINICAL ONCOLOGY
- Production of CAR T-cells by GMP-grade lentiviral vectors: Latest advances and future prospects
- (2019) Mansour Poorebrahim et al. CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES
- Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results From the Phase I/II CheckMate 358 Trial
- (2019) R. Wendel Naumann et al. JOURNAL OF CLINICAL ONCOLOGY
- 1210PPhase Ib/II trial of TG4001 (Tipapkinogene sovacivec), a therapeutic HPV-vaccine, and Avelumab in patients with recurrent/metastatic (R/M) HPV-16+ cancers
- (2019) C Le Tourneau et al. ANNALS OF ONCOLOGY
- A phase 2, prospective, randomized, multicenter, open-label study of GX-188E, an HPV DNA vaccine, in patients with cervical intraepithelial neoplasia 3
- (2019) Youn Jin Choi et al. CLINICAL CANCER RESEARCH
- A randomized phase III trial of platinum chemotherapy plus paclitaxel with bevacizumab and atezolizumab versus platinum chemotherapy plus paclitaxel and bevacizumab in metastatic (stage IVB), persistent, or recurrent carcinoma of the cervix: the BEATcc study (ENGOT-Cx10/GEICO 68-C/JGOG1084/GOG-3030)
- (2019) Juan Francisco Grau et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study
- (2019) Barbara Burtness et al. LANCET
- Evolving Roles for Targeting CTLA-4 in Cancer Immunotherapy
- (2018) Yinghao Zhao et al. CELLULAR PHYSIOLOGY AND BIOCHEMISTRY
- A Randomized Phase 2 Study of ADXS11-001 Listeria monocytogenes–Listeriolysin O Immunotherapy With or Without Cisplatin in Treatment of Advanced Cervical Cancer
- (2018) Partha Basu et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- Clinical use of lentiviral vectors
- (2018) Michael C. Milone et al. LEUKEMIA
- T cell receptor repertoire among women who cleared and failed to clear cervical human papillomavirus infection: An exploratory proof-of-principle study
- (2018) Krystle A. Lang Kuhs et al. PLoS One
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Combining Immune Checkpoint Blockade and Tumor-Specific Vaccine for Patients With Incurable Human Papillomavirus 16–Related Cancer
- (2018) Erminia Massarelli et al. JAMA Oncology
- A phase II study of tumor-infiltrating lymphocyte therapy for human papillomavirus-associated epithelial cancers
- (2018) Sanja Stevanovic et al. CLINICAL CANCER RESEARCH
- Worldwide burden of cancer attributable to HPV by site, country and HPV type
- (2017) Catherine de Martel et al. INTERNATIONAL JOURNAL OF CANCER
- T-cell receptor-engineered T cells for cancer treatment: current status and future directions
- (2017) Yu Ping et al. Protein & Cell
- Systematic comparison of 2A peptides for cloning multi-genes in a polycistronic vector
- (2017) Ziqing Liu et al. Scientific Reports
- Avidity characterization of genetically engineered T-cells with novel and established approaches
- (2016) Victoria Hillerdal et al. BMC IMMUNOLOGY
- Flow cytometry-based TCR-ligandKoff-rate assay for fast avidity screening of even very small antigen-specific T cell populations ex vivo
- (2016) Magdalena Nauerth et al. CYTOMETRY PART A
- Targeting immune response with therapeutic vaccines in premalignant lesions and cervical cancer: hope or reality from clinical studies
- (2016) P Vici et al. Expert Review of Vaccines
- A pilot study of pNGVL4a-CRT/E7(detox) for the treatment of patients with HPV16 + cervical intraepithelial neoplasia 2/3 (CIN2/3)
- (2016) Ronald D. Alvarez et al. GYNECOLOGIC ONCOLOGY
- Assessment of costimulation and coinhibition in a triple parameter T cell reporter line: Simultaneous measurement of NF-κB, NFAT and AP-1
- (2016) Sabrina Jutz et al. JOURNAL OF IMMUNOLOGICAL METHODS
- Retroviral vectors and transposons for stable gene therapy: advances, current challenges and perspectives
- (2016) José Eduardo Vargas et al. Journal of Translational Medicine
- Targeting of HPV-16+ Epithelial Cancer Cells by TCR Gene Engineered T Cells Directed against E6
- (2015) L. M. Draper et al. CLINICAL CANCER RESEARCH
- From the monovalent to the nine-valent HPV vaccine
- (2015) S. Pils et al. CLINICAL MICROBIOLOGY AND INFECTION
- Genetically modified T cells in cancer therapy: opportunities and challenges
- (2015) M. Sharpe et al. Disease Models & Mechanisms
- Complete Regression of Metastatic Cervical Cancer After Treatment With Human Papillomavirus–Targeted Tumor-Infiltrating T Cells
- (2015) Sanja Stevanović et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase I dose-escalation clinical trial of a peptide-based human papillomavirus therapeutic vaccine withCandidaskin test reagent as a novel vaccine adjuvant for treating women with biopsy-proven cervical intraepithelial neoplasia 2/3
- (2015) William W Greenfield et al. OncoImmunology
- Phase I/II study of ADXS11-001 or MEDI4736 immunotherapies alone and in combination, in patients with recurrent/metastatic cervical or human papillomavirus (HPV)-positive head and neck cancer
- (2015) Ezra EW Cohen et al. Journal for ImmunoTherapy of Cancer
- Zinc Finger Nucleases Targeting the Human Papillomavirus E7 Oncogene Induce E7 Disruption and a Transformed Phenotype in HPV16/18-Positive Cervical Cancer Cells
- (2014) W. Ding et al. CLINICAL CANCER RESEARCH
- Minicircle DNA vectors for gene therapy: advances and applications
- (2014) Vítor Gaspar et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- TALEN-mediated targeting of HPV oncogenes ameliorates HPV-related cervical malignancy
- (2014) Zheng Hu et al. JOURNAL OF CLINICAL INVESTIGATION
- Intramuscular Therapeutic Vaccination Targeting HPV16 Induces T Cell Responses That Localize in Mucosal Lesions
- (2014) L. Maldonado et al. Science Translational Medicine
- Incorporation of Transmembrane Hydrophobic Mutations in the TCR Enhance Its Surface Expression and T Cell Functional Avidity
- (2012) A. Haga-Friedman et al. JOURNAL OF IMMUNOLOGY
- Human Papillomavirus Type 16 E6/E7-specific Cytotoxic T Lymphocytes for Adoptive Immunotherapy of HPV-associated Malignancies
- (2012) Carlos A. Ramos et al. JOURNAL OF IMMUNOTHERAPY
- Immunotherapy for Cervical Cancer
- (2010) Jun-Han Su et al. BIODRUGS
- Perspectives for Preventive and Therapeutic HPV Vaccines
- (2010) Ken Lin et al. JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION
- Costimulatory and coinhibitory receptors in anti-tumor immunity
- (2009) Gregory Driessens et al. IMMUNOLOGICAL REVIEWS
- A Phase I Trial of a Human Papillomavirus DNA Vaccine for HPV16+ Cervical Intraepithelial Neoplasia 2/3
- (2008) C. L. Trimble et al. CLINICAL CANCER RESEARCH
- Development of optimal bicistronic lentiviral vectors facilitates high-level TCR gene expression and robust tumor cell recognition
- (2008) S Yang et al. GENE THERAPY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started